ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1855

Feasibility and Preliminary Effects of a Novel Rehabilitation Strategy to Improve Hand and Arm Function in Systemic Sclerosis

Susan L. Murphy1, Mary Barber2, Kristen Homer3, Carole Dodge2 and Dinesh Khanna4, 1Phyiscal Medicine & Rehabilitation, University of Michigan, Ann Arbor, MI, 2Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI, 3Department of Internal Medicine, Rheumatology Division, University of Michigan, Ann Arbor, MI, 4University of Michigan, Ann Arbor, MI

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Occupational therapy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: ACR/ARHP Combined: Orthopedics and Rehabilitation Science

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Individuals with systemic sclerosis (SSc) suffer from limited arm and hand function due to skin thickening and contractures. Evidence-based medical rehabilitation strategies for these issues remain limited. Standard treatments of heat massage, and exercise are recommended but are primarily focused on the hand, not taking into account wrist, elbow, and shoulder contractures. In addition the rehabilitation treatments do not often target the skin scarring that underlies contracture formation. The purpose of this study was to determine the feasibility and preliminary effects of a novel treatment approach to improve arm and hand function in patients with scleroderma with both arm and hand contractures.

Methods: Participants with early SSc with arm and hand contractures were recruited from our Scleroderma Clinic. The intervention involved eight in-person weekly sessions with an occupational therapist and involved heat, mobility and range of motion exercises, and the use of the Physiotouch®, a negative pressure device that is commonly used at our center in other patient populations for mobilizing tissue with positive effects on the lymphatic system and skin mobilization. Feasibility was assessed by determining participant flow through the trial including the number of people enrolled who were eligible, and the number of people that adhered to the entire treatment protocol. A secondary goal was to examine preliminary effects on arm and hand function using the QuickDASH disability measure. Primary outcomes were measured at baseline and 8 weeks with an intermediate assessment at 4 weeks post baseline.

Results: The sample (N = 16) had a mean age of 46 (range 22-67), was 88% female, and 44% indicated being from racial minority group. The sample are diffuse scleroderma subset with a mean Rodnan skin score of 17.9 (+/- 10.1), and a mean QuickDASH score was 53.4 (+/- 22.7), which is almost three standard deviations above the population mean. Of those screened in-person, 95% were eligible, and 90% were enrolled. 50% have currently adhered to the entire protocol. 50% of our sample who have so far completed treatment at 8 weeks had improvements on the QuickDASH (n = 8) which ranged between 6-13 points, the mean improvement was statistically significant (t=6.6, df=7, p = .0001). Participants reported positive outcomes of the treatment such as improved coordination, fluidity of movement, not dropping things, and pain improvement.

Conclusion: This intervention is feasible despite the burden of traveling to the center for 8 in-person visits and led to improvements in half of the participants. This study would benefit from bolstering home rehabilitation components and future work will need to compare those who receive this treatment to a control group.


Disclosure: S. L. Murphy, None; M. Barber, None; K. Homer, None; C. Dodge, None; D. Khanna, Actelion, Bayer, BoehringerIngelheim, Chemomab, Corbus, Covis, Cytori,Eicos, EMD Serono, Genentech/Roche, Gilead, GSK, Sanofi-Aventis,UCB Pharma, 5,NIH/NIAMS, NIH/NIAID,Bayer, BMS, Genentech/Roche, Pfizer, 2,Eicos, 4.

To cite this abstract in AMA style:

Murphy SL, Barber M, Homer K, Dodge C, Khanna D. Feasibility and Preliminary Effects of a Novel Rehabilitation Strategy to Improve Hand and Arm Function in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/feasibility-and-preliminary-effects-of-a-novel-rehabilitation-strategy-to-improve-hand-and-arm-function-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/feasibility-and-preliminary-effects-of-a-novel-rehabilitation-strategy-to-improve-hand-and-arm-function-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology